Published in Proc Natl Acad Sci U S A on September 04, 2012
Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci (2015) 1.25
Neurostimulation of the cholinergic anti-inflammatory pathway ameliorates disease in rat collagen-induced arthritis. PLoS One (2014) 1.03
Control of bone remodeling by the peripheral sympathetic nervous system. Calcif Tissue Int (2013) 0.85
Expression of non-neuronal cholinergic system in maxilla of rat in vivo. Biol Res (2014) 0.78
Evolution of the Marrow Adipose Tissue Microenvironment. Calcif Tissue Int (2016) 0.77
Expression of muscarinic acetylcholine receptors M3 and M5 in osteoporosis. Med Sci Monit (2014) 0.76
Nicotinic acetylcholine receptors modulate osteoclastogenesis. Arthritis Res Ther (2016) 0.76
Small changes in bone structure of female α7 nicotinic acetylcholine receptor knockout mice. BMC Musculoskelet Disord (2015) 0.76
Sympathetic Neurotransmitters Modulate Osteoclastogenesis and Osteoclast Activity in the Context of Collagen-Induced Arthritis. PLoS One (2015) 0.75
Bone mass is regulated by a central IL-1-PSNS-bone axis. Bonekey Rep (2012) 0.75
Donepezil prevents RANK-induced bone loss via inhibition of osteoclast differentiation by downregulating acetylcholinesterase. Heliyon (2015) 0.75
Early Evidence of Low Bone Density and Decreased Serotonergic Synthesis in the Dorsal Raphe of a Tauopathy Model of Alzheimer's Disease. J Alzheimers Dis (2016) 0.75
Involvement of the Nonneuronal Cholinergic System in Bone Remodeling in Rat Midpalatal Suture after Rapid Maxillary Expansion. Biomed Res Int (2016) 0.75
Pth4, an ancient parathyroid hormone lost in eutherian mammals, reveals a new brain-to-bone signaling pathway. FASEB J (2016) 0.75
Cholinergic Modulation of the Immune System Presents New Approaches for Treating Inflammation. Pharmacol Ther (2017) 0.75
Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell (2006) 7.23
Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature (2005) 6.43
Therapeutic approaches to bone diseases. Science (2000) 5.60
Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol (2007) 5.48
International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev (1998) 5.34
Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci U S A (2008) 2.58
The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxicol (1994) 1.97
Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron (2011) 1.82
Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function. Methods Enzymol (1997) 1.81
d-Tubocurarine binding sites are located at alpha-gamma and alpha-delta subunit interfaces of the nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A (1990) 1.78
Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci (2010) 1.71
Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity. Hippocampus (2003) 1.52
Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci (2002) 1.50
Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles. Proc Natl Acad Sci U S A (1996) 1.45
Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinology (2004) 1.42
Characterization of the central nervous system innervation of the rat spleen using viral transneuronal tracing. J Comp Neurol (2001) 1.39
Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci (Landmark Ed) (2009) 1.38
Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S A (2006) 1.22
Central autonomic control of the bone marrow: multisynaptic tract tracing by recombinant pseudorabies virus. Neuroscience (2005) 1.13
Major depression is a risk factor for low bone mineral density: a meta-analysis. Biol Psychiatry (2009) 1.10
Sleep. A physiologic role for IL-1 beta and TNF-alpha. Ann N Y Acad Sci (1998) 1.08
Physiology, assessment, and disorders of the pupil. Curr Opin Ophthalmol (1999) 1.08
Nicotine modulates bone metabolism-associated gene expression in osteoblast cells. J Bone Miner Metab (2009) 1.07
Relationships between the autonomic nervous system and the pancreas including regulation of regeneration and apoptosis: recent developments. Pancreas (2004) 1.06
Nicotinic cholinergic receptors in the rat retina: simple and mixed heteromeric subtypes. Mol Pharmacol (2005) 1.06
Central IL-1 receptor signaling regulates bone growth and mass. Proc Natl Acad Sci U S A (2005) 1.04
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J (2007) 1.04
Neuroendocrinological aspects of epilepsy: important issues and trends in future research. Epilepsy Behav (2011) 1.01
Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A (2010) 0.99
Signaling through the M(3) muscarinic receptor favors bone mass accrual by decreasing sympathetic activity. Cell Metab (2010) 0.96
Distribution of the vesicular acetylcholine transporter (VAChT) in the central and peripheral nervous systems of the rat. J Mol Neurosci (1994) 0.96
Evolving concepts in neurogenic osteoporosis. Curr Osteoporos Rep (2010) 0.95
Functional role of acetylcholine and the expression of cholinergic receptors and components in osteoblasts. FEBS Lett (2010) 0.95
Expression of non-neuronal cholinergic system in osteoblast-like cells and its involvement in osteogenesis. Cell Tissue Res (2009) 0.95
Human osteoclasts express oxytocin receptor. Biochem Biophys Res Commun (2002) 0.95
Pharmacological and immunochemical characterization of alpha2* nicotinic acetylcholine receptors (nAChRs) in mouse brain. Acta Pharmacol Sin (2009) 0.92
Pathophysiology underlying irritable bowel syndrome--from the viewpoint of dysfunction of autonomic nervous system activity. J Smooth Muscle Res (2009) 0.91
What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem Pharmacol (1989) 0.89
ON THE FORMATION OF ACETYLCHOLINE IN THE NERVE AXON. Science (1945) 0.88
Evolution of and perspectives on therapeutic approaches to nerve agent poisoning. Toxicol Lett (2011) 0.87
Transneuronal mapping of the CNS network controlling sympathetic outflow to the rat thymus. Auton Neurosci (2006) 0.86
Morphology and physiology of salivary myoepithelial cells. Int Rev Physiol (1977) 0.83
Muscarinic acetylcholine receptors present in human osteoblast and bone tissue. Eur J Pharmacol (2010) 0.83
Disorders of the autonomic nervous system. Chapter 3. The nervous control of the circulation and its investigation. Contemp Neurol Ser (1974) 0.83
Intracerebroventricular injection of interleukin-1 suppresses peripheral lymphocyte function in the primate. Neuroimmunomodulation (1997) 0.82
Neuronal-type acetylcholine receptors and regulation of alpha 7 gene expression in vertebrate skeletal muscle. J Neurobiol (1997) 0.80
Vagal afferents are necessary for the establishment but not the maintenance of kainic acid-induced hyperalgesia in mice. Pain (2003) 0.79
Cat heart acetylcholine: structural proof and distribution. Am J Physiol (1976) 0.79
FSH directly regulates bone mass. Cell (2006) 4.64
Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab (2008) 2.33
Vav3 regulates osteoclast function and bone mass. Nat Med (2005) 2.30
c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest (2003) 2.19
Reversible modulations of neuronal plasticity by VEGF. Proc Natl Acad Sci U S A (2011) 2.06
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology (2007) 1.77
Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by beta3 integrin. J Cell Biol (2003) 1.65
Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes. Proc Natl Acad Sci U S A (2013) 1.54
Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun (2005) 1.53
Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity. Hippocampus (2003) 1.52
Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci U S A (2008) 1.46
Interleukin-1 (IL-1): a central regulator of stress responses. Front Neuroendocrinol (2008) 1.46
Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci U S A (2009) 1.44
Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun (2011) 1.44
Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures. Eur J Cardiothorac Surg (2013) 1.41
Low levels of circulating inflammatory cytokines--do they affect human brain functions? Brain Behav Immun (2002) 1.38
Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood (2010) 1.38
The role of prior stressor controllability and the dorsal raphé nucleus in sucrose preference and social exploration. Behav Brain Res (2008) 1.36
Prediction of fracture callus mechanical properties using micro-CT images and voxel-based finite element analysis. Bone (2005) 1.33
NLRP3-Inflammasome Activating DAMPs Stimulate an Inflammatory Response in Glia in the Absence of Priming Which Contributes to Brain Inflammation after Injury. Front Immunol (2012) 1.33
Systemic inflammatory challenges compromise survival after experimental stroke via augmenting brain inflammation, blood- brain barrier damage and brain oedema independently of infarct size. J Neuroinflammation (2011) 1.32
Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone (2008) 1.32
Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. Pain (2005) 1.27
Novel tracing paradigms--genetically engineered herpesviruses as tools for mapping functional circuits within the CNS: present status and future prospects. Prog Neurobiol (2004) 1.25
Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S A (2006) 1.22
Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab (2012) 1.20
Intrahippocampal transplantation of transgenic neural precursor cells overexpressing interleukin-1 receptor antagonist blocks chronic isolation-induced impairment in memory and neurogenesis. Neuropsychopharmacology (2007) 1.18
Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment. Int J Neuropsychopharmacol (2002) 1.18
Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc Natl Acad Sci U S A (2013) 1.17
Effects of antidepressants on cytokine production and actions. Brain Behav Immun (2002) 1.16
Cholinergic status modulations in human volunteers under acute inflammation. J Mol Med (Berl) (2007) 1.15
Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet (2005) 1.13
Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology (2007) 1.13
Interleukin-1α expression precedes IL-1β after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues. J Neuroinflammation (2011) 1.12
Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass. J Cell Physiol (2006) 1.11
Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA. J Immunol (2012) 1.10
Major depression is a risk factor for low bone mineral density: a meta-analysis. Biol Psychiatry (2009) 1.10
A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am J Pathol (2005) 1.10
Environmental enrichment restores memory functioning in mice with impaired IL-1 signaling via reinstatement of long-term potentiation and spine size enlargement. J Neurosci (2009) 1.08
Lef1 haploinsufficient mice display a low turnover and low bone mass phenotype in a gender- and age-specific manner. PLoS One (2009) 1.08
Peroxidasin is secreted and incorporated into the extracellular matrix of myofibroblasts and fibrotic kidney. Am J Pathol (2009) 1.07
Recovery of the soleus muscle after short- and long-term disuse induced by hindlimb unloading: effects on the electrical properties and myosin heavy chain profile. Neurobiol Dis (2005) 1.06
Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann Neurol (2005) 1.05
Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton. J Biol Chem (2012) 1.05
Central IL-1 receptor signaling regulates bone growth and mass. Proc Natl Acad Sci U S A (2005) 1.04
Visualization of stress-responsive inhibitory circuits in the GAD65-eGFP transgenic mice. Neurosci Lett (2005) 1.04
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J (2007) 1.04
Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proc Natl Acad Sci U S A (2012) 1.04
Involvement of Na(+), K(+)-ATPase and endogenous digitalis-like compounds in depressive disorders. Biol Psychiatry (2006) 1.03
Impairment of interleukin-1 (IL-1) signaling reduces basal pain sensitivity in mice: genetic, pharmacological and developmental aspects. Pain (2003) 1.03
M-CSF regulates the cytoskeleton via recruitment of a multimeric signaling complex to c-Fms Tyr-559/697/721. J Biol Chem (2007) 1.03
Microgravity during spaceflight directly affects in vitro osteoclastogenesis and bone resorption. FASEB J (2009) 1.02
Neuronal Toll-like receptor 4 signaling induces brain endothelial activation and neutrophil transmigration in vitro. J Neuroinflammation (2012) 1.02
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood (2004) 1.02
Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. J Cell Sci (2002) 1.02
Endosseous implant anchorage is critically dependent on mechanostructural determinants of peri-implant bone trabeculae. J Bone Miner Res (2010) 1.02
Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol (2006) 1.01
IL-1 beta signaling is required for mechanical allodynia induced by nerve injury and for the ensuing reduction in spinal cord neuronal GRK2. Brain Behav Immun (2007) 1.01
Oxytocin deficiency impairs maternal skeletal remodeling. Biochem Biophys Res Commun (2009) 1.00
Thyroid-stimulating hormone, thyroid hormones, and bone loss. Curr Osteoporos Rep (2009) 1.00
Astrocytes support hippocampal-dependent memory and long-term potentiation via interleukin-1 signaling. Brain Behav Immun (2010) 1.00
Stimulation of osteoclast activity by low B-vitamin concentrations. Bone (2007) 0.99
Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A (2010) 0.99
Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. Biochem Biophys Res Commun (2011) 0.99
Interleukin-1 signaling is required for induction and maintenance of postoperative incisional pain: genetic and pharmacological studies in mice. Brain Behav Immun (2008) 0.98
Transplanted blood-derived endothelial progenitor cells (EPC) enhance bridging of sheep tibia critical size defects. Bone (2009) 0.98
Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem (2005) 0.98
The immune system in stroke: clinical challenges and their translation to experimental research. J Neuroimmune Pharmacol (2013) 0.96
Human osteoclasts express oxytocin receptor. Biochem Biophys Res Commun (2002) 0.95
Intracerebral HIV-1 glycoprotein 120 produces sickness behavior and pituitary-adrenal activation in rats: role of prostaglandins. Brain Behav Immun (2002) 0.95
Elevated glucocorticoid levels are responsible for induction of tyrosine hydroxylase mRNA expression, phosphorylation, and enzyme activity in the nucleus of the solitary tract during morphine withdrawal. Endocrinology (2009) 0.94
The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis (2007) 0.94
Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann N Y Acad Sci (2011) 0.94
Activation of stress-related hypothalamic neuropeptide gene expression during morphine withdrawal. J Neurochem (2007) 0.94
CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res (2011) 0.94
Bacterial infection early in life protects against stressor-induced depressive-like symptoms in adult rats. Psychoneuroendocrinology (2008) 0.94
N-Acyl amino acids and their impact on biological processes. Biofactors (2014) 0.93
Osteogenic growth peptide modulates fracture callus structural and mechanical properties. Bone (2004) 0.93
Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease. J Bone Miner Res (2005) 0.93
Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury. Eur J Pain (2010) 0.92
Targeting IL-1 in depression. Expert Opin Ther Targets (2012) 0.92
Systemic immune activation shapes stroke outcome. Mol Cell Neurosci (2012) 0.92
First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant. Neuromuscul Disord (2006) 0.92